Boston Scientific Corp. vs. ClearPoint Neuro, Inc. Common Stock
Boston Scientific Corp. and ClearPoint Neuro, Inc. Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| BSX | CLPT | |
|---|---|---|
| Market Cap | $69.19 billion | $401.44 million |
| Revenue (TTM) | $21.00 billion | — |
| Net Income (TTM) | $3.67 billion | — |
BSX leads on 1 of 1 size & scale factors.
Valuation
| BSX | CLPT | |
|---|---|---|
| P/E Ratio | 19.33 | — |
| Price / Book | 2.75 | — |
| Price / Sales | 3.30 | — |
BSX and CLPT split the valuation factors evenly.
Profitability
| BSX | CLPT | |
|---|---|---|
| Net Margin | 17.47% | — |
| Return on Equity | 14.57% | — |
BSX and CLPT split the profitability factors evenly.
Risk & Sentiment
| BSX | CLPT | |
|---|---|---|
| Short Interest | 0.70% | 0.17% |
CLPT leads on 1 of 1 risk & sentiment factors.
Dig deeper: BSX overview, BSX financials, CLPT overview, CLPT financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.